Home - Translational Lung Cancer Research

New Impact Factor for Translational Lung Cancer Research: 4

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2023 citation year: 4.

Translational Lung Cancer Research 2023 CiteScore Released: 7.2

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has received its 2023 CiteScore: 7.2, ranking 92 out of 404 journals in the Oncology category.

Furthermore, we are delighted to highlight the remarkable achievements made by all AME journals in the CiteScore ranking.

Interviews with Outstanding Authors (2024)

In 2024, many authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors, with a brief interview of their thoughts and insights as authors. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Reviewer of the Month (2024)

In 2024, TLCR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

TLCR Annual Report 2023

Welcome to the 2023 annual report for Translational Lung Cancer Research. In 2023, the TLCR has continued its mission to increase the quality and impact of the journal, and to provide readers with a novel, well-organized, informative, enlightening and educational journal.

We would like to sincerely thank our Editorial Board Members, Guest editors, Reviewers, Authors, Readers for all your supports and contributions to TLCR in 2023, and we look forward to continuing our work with you in the new year.

‹ ›

Vol 13, No 6 (June, 2024)

Articles in Press

Past Issues

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

TLCR Chinese Edition more

免疫治疗是晚期非小细胞肺癌去化疗的关键，或还是未到时候？

免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）改变了缺乏驱动基因突变的晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗... More >>

晚期或转移性非小细胞肺癌一线免疫治疗中，肿瘤细胞PD-L1表达的阈值究竟在哪

对于晚期或转移性非小细胞肺癌（non-small cell lung cancer，NSCLC），一线免疫治疗对部分患者来说，可以获得比单纯化疗更好的总生存率获益。 More >>

KEYNOTE-042研究：降低帕博利珠单抗单药一线治疗的PD-L1阈值是个好主意吗？

在针对程序性死亡1（programmed death 1，PD-1）或程序性死亡配体1（programmed death ligand 1，PD-L1）的抑制性抗体出现之前，晚期/转移性非小细胞肺癌（... More >>

Editorial

Adaptive medicine, a crucial component of optimized decision making: perspectives from lung cancer management

Wenhua Liang, Ran Zhong, Jianxing He

PDF Pages: 1185-1189 Full Text (62) Peer Review File COI Form Open Access

Original Article

The impact of different modalities of chemoradiation therapy and chemotherapy regimens on lymphopenia in patients with locally advanced non-small cell lung cancer

Yaqi Li, Xingwen Fan, Yulei Pei, Qi Yu, Renquan Lu, Guoliang Jiang, Kailiang Wu

PDF Pages: 1190-1200 Full Text (68) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Segmentectomy versus lobectomy for ground-glass opacity dominant cT1N0 invasive lung adenocarcinoma

Zelin Ma, Yang Zhang, Han Han, Shengping Wang, Yuan Li, Haiquan Chen

PDF Pages: 1201-1209 Full Text (53) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Association between strenuous sports or other exercises and lung cancer risk: a mendelian randomization study

Wushu Chen, Anlin Liu, Yu Jiang, Yuechun Lin, Xingpei Li, Chongde Pan, Yixuan Wang, Huiwen Yu, Yulin Zhao, Junxing Li, Hengrui Liang, Runchen Wang, Wei Wang, Xin Xu, Ying Huang

PDF Pages: 1210-1221 Full Text (48) Reporting Checklist Peer Review File COI Form Open Access

Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and multifocal lung adenocarcinoma

Jiahao Jiang, Mark F. Berry, Natalie S. Lui, Douglas Z. Liou, Winston L. Trope, Leah M. Backhus, Joseph B. Shrager

PDF Pages: 1222-1231 Full Text (53) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Predicting MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma by whole-tumour texture analysis combined with clinical and conventional contrast-enhanced computed tomography features

Lei Miao, Tian Qiu, Yan Li, Jianwei Li, Xu Jiang, Mengwen Liu, Xue Zhang, Jiuming Jiang, Huanhuan Zhang, Yanmei Wang, Xiao Li, Jianming Ying, Meng Li

PDF Pages: 1232-1246 Full Text (37) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Predictive value of delta-radiomic features for prognosis of advanced non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy

Xiaoyu Han, Yujin Wang, Xi Jia, Yuting Zheng, Chengyu Ding, Xiaohui Zhang, Kailu Zhang, Yunkun Cao, Yumin Li, Liming Xia, Chuansheng Zheng, Jing Huang, Heshui Shi

PDF Pages: 1247-1263 Full Text (34) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups

Chuanwang Miao, Yuanji Chen, Hao Zhang, Wei Zhao, Cunliang Wang, Zeliang Ma, Shan Zhu, Xudong Hu

PDF Pages: 1264-1276 Full Text (44) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Bioinformatics analysis of an immunotherapy responsiveness-related gene signature in predicting lung adenocarcinoma prognosis

Yupeng Jiang, Bacha Hammad, Hong Huang, Chenzi Zhang, Bing Xiao, Linxia Liu, Qimi Liu, Hengxing Liang, Zhenyu Zhao, Yawen Gao

PDF Pages: 1277-1295 Full Text (38) Reporting Checklist Peer Review File COI Form Open Access

Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical data

Sheng Lu, Aotian Guo, Haichuan Hu, Xinxin Ying, Yao Li, Zhengwei Huang, Wangjue Xu, Shen Tao, Xiaotong Hu, Na Yan, Xuan Zhang, Dan Shen, Takaaki Sasaki, Surein Arulananda, Ken Onodera, Zhengfu He

PDF Pages: 1296-1306 Full Text (59) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study

Yanfei Chen, Tong Liu, Hui Feng, Tiantian Liu, Jing Zhang, Jun Wang, Jihong Lu, Antonio Rossi, Ivy Riano, Pingping Hu, Jiandong Zhang

PDF Pages: 1307-1317 Full Text (51) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Predicting complication risks after sleeve lobectomy for non-small cell lung cancer

Yiming He, Lin Huang, Jiajun Deng, Yifan Zhong, Tao Chen, Yunlang She, Lei Jiang, Deping Zhao, Dong Xie, Gening Jiang, Stefano Bongiolatti, Mara B. Antonoff, René Horsleben Petersen, Chang Chen

PDF Pages: 1318-1330 Full Text (55) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

PSME3 promotes lung adenocarcinoma development by regulating the TGF-β/SMAD signaling pathway

Shuai Wang, Yongmeng Li, Kai Jin, Kenichi Suda, Rongyang Li, Huiying Zhang, Hui Tian

PDF Pages: 1331-1345 Full Text (60) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Peptidyl-prolyl isomerase F as a prognostic biomarker associated with immune infiltrates and mitophagy in lung adenocarcinoma

Zitong Feng, Lin Yuan, Luyuan Ma, Wenhao Yu, Fayez Kheir, Lukas Käsmann, Wolfgang M. Brueckl, Kai Jin, Dingxin Wang, Yi Shen, Rongyang Li, Hui Tian

PDF Pages: 1346-1364 Full Text (34) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Tumor mutation burden and FAT3 mutation influence long-term survival in surgically resected small cell lung cancer

Xinyu Qian, Lin Zhu, Na Han, Jing Qin

PDF Pages: 1365-1375 Full Text (54) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Pathological and imaging features of pulmonary invasive mucinous adenocarcinoma—a retrospective cohort study

Xinfu Pan, Renxiu Fang, Binjie Zhang, Zhijun Chen, Shanhua Zhang, Hanbo Le, Helmut H. Popper, Lu Liu, Yongkui Zhang

PDF Pages: 1376-1382 Full Text (53) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Review Article

Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments

Xinchen Zhao, Shengwei Zhang, Xiaoyue Sun, Yao Lin, Luca Capone, Eric C. Ko, Benjamin H. Kann, Yi Li, Xiaoshan Wang

PDF Pages: 1383-1395 Full Text (61) Reporting Checklist Peer Review File COI Form Open Access

Case Report: iMDT Corner

Radical resection in a patient with stage IIIA non-small cell lung cancer with the EGFR exon 19 deletion mutation after neoadjuvant targeted therapy with osimertinib: a case report

Hao Chen, Jiarong Zhang, Atsushi Osoegawa, Lorenzo Calvetti, Palma Fedele, Chun Chen, Bin Zheng

PDF Pages: 1396-1406 Full Text (60) Reporting Checklist Peer Review File COI Form Open Access

Case Report

Prominent response to savolitinib monotherapy in high-grade fetal adenocarcinoma with MET amplification and concurrent brain metastasis: a case report

Lan Shen, Jikai Zhao, Ying Yang, Shuya Mu, Yongfeng Yu, Yuchen Han, Shun Lu

PDF Pages: 1407-1413 Full Text (61) Reporting Checklist Peer Review File COI Form Open Access

Neoadjuvant aumolertinib monotherapy for EGFR-mutant lung squamous cell carcinoma: a case report

Yue Liu, Xiaoxia Yan, Dongliang Bian, Kaixing Ai, Yuming Zhu

PDF Pages: 1414-1419 Full Text (32) Reporting Checklist Peer Review File COI Form Open Access

Major pathological response obtained after neoadjuvant chemotherapy combined with dual immunotherapy for malignant pleural mesothelioma: a case report

Yuchen Zhang, Guangyin Zhao, Chen Xu, Jie Gu, Di Ge

PDF Pages: 1420-1425 Full Text (49) Reporting Checklist Peer Review File COI Form Open Access

Editorial Commentary

The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity

Dariusz M. Kowalski, Magdalena Zaborowska-Szmit, Sebastian Szmit, Piotr Jaśkiewicz, Maciej Krzakowski

PDF Pages: 1426-1431 Full Text (54) Peer Review File COI Form Open Access

The APPLE trial in the evolving landscape of ctDNA monitoring

Danielle Brazel, Misako Nagasaka

PDF Pages: 1432-1437 Full Text (53) Peer Review File COI Form Open Access

Diagnosis and treatment of non-small cell lung cancer (NSCLC) harboring MET Ex14 skipping: have we met the desired drug?

Go Makimoto

PDF Pages: 1438-1443 Full Text (31) Peer Review File COI Form Open Access

Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer

Julie Moeller, Michael D. Green, Nithya Ramnath

PDF Pages: 1444-1449 Full Text (34) Peer Review File COI Form Open Access

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Sublobar resection for lung adenocarcinoma less than 2 cm containing solid or micropapillary components radiologically presented as consolidation-to-tumor ratio (CTR) ≤0.25 [ground-glass opacity (GGO)]

Mingyang Zhu, Yuanyuan Xu, Jiazheng Huang, Yaxian Yao, Davide Tosi, Terumoto Koike, Nestor R. Villamizar, Ziang Wang, Feng Mao, Qingquan Luo, Qiang Tan

Published online: 19 June 2024

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.